Vanguard Group Inc trimmed its holdings in shares of Catalyst Biosciences Inc (NASDAQ:CBIO) by 0.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 551,684 shares of the biopharmaceutical company’s stock after selling 2,453 shares during the quarter. Vanguard Group Inc’s holdings in Catalyst Biosciences were worth $5,947,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of CBIO. Schwab Charles Investment Management Inc. bought a new position in Catalyst Biosciences during the second quarter valued at $297,000. Hikari Power Ltd purchased a new stake in shares of Catalyst Biosciences during the third quarter valued at about $323,000. JBF Capital Inc. acquired a new position in shares of Catalyst Biosciences during the third quarter valued at about $323,000. Wells Fargo & Company MN increased its holdings in shares of Catalyst Biosciences by 47.2% during the third quarter. Wells Fargo & Company MN now owns 50,397 shares of the biopharmaceutical company’s stock valued at $544,000 after acquiring an additional 16,165 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Catalyst Biosciences by 86.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,811 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 26,829 shares during the period. 67.62% of the stock is owned by hedge funds and other institutional investors.
Shares of CBIO stock traded up $0.05 during mid-day trading on Monday, hitting $8.34. 633 shares of the stock traded hands, compared to its average volume of 283,219. The stock has a market cap of $99.05 million, a PE ratio of -1.12 and a beta of 2.51. Catalyst Biosciences Inc has a twelve month low of $6.20 and a twelve month high of $37.00.
Several research firms have commented on CBIO. CIBC initiated coverage on Catalyst Biosciences in a research report on Friday, January 4th. They issued an “outperform” rating and a $24.00 price objective on the stock. Oppenheimer assumed coverage on Catalyst Biosciences in a research report on Friday, January 4th. They set an “outperform” rating and a $24.00 price objective for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $35.00 price objective on shares of Catalyst Biosciences in a research note on Thursday, December 20th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Catalyst Biosciences presently has an average rating of “Buy” and a consensus price target of $21.50.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2019/02/11/vanguard-group-inc-sells-2453-shares-of-catalyst-biosciences-inc-cbio.html.
About Catalyst Biosciences
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Recommended Story: Benefits of owning preferred stock
Want to see what other hedge funds are holding CBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Biosciences Inc (NASDAQ:CBIO).
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.